![]() MVA-VLP-SUDV combines the advantages of the authentic conformation of VLPs with the immunogenicity and safety of a live, attenuated virus vector. ![]() Our Modified Vaccinia Ankara virus-like particle (MVA-VLP) vaccine platform was used to develop the vaccine candidate MVA-VLP-SUDV, which expresses the minimal components required for self-assembling filovirus VLPs: the glycoprotein GP and the matrix protein VP40 12. Modified Vaccinia Ankara (MVA) is well suited as a viral vaccine platform because of its excellent safety profile, immunogenicity, thermostability, genome coding capacity for multi-antigen expression and the lack of impairment of protective immune response by pre-existing orthopoxvirus-specific immunity 11. ![]() However, there is currently no approved vaccine against SUDV, although several vaccine candidates were demonstrated to protect laboratory animals against the disease in preclinical studies 6, 7, 8, 9, 10. Biomedical Advanced Research and Development Authority (BARDA) which goals include having a monovalent SUDV vaccine in the next decade 5. As such, development of safe and efficacious vaccines is a high priority for the WHO and the U.S. The extremely high case fatality rate, the significant transmissibility of SUDV and its potential use as a biological warfare and bioterrorism weapon underscore the importance of countermeasures against this virus. Since its discovery in 1976, SUDV triggered eight outbreaks that infected 779 people and killed 412 people – 53% of infected people the virus is responsible for the greatest number of ebolavirus outbreaks after EBOV 4. ![]() Recently, two vaccines against the deadliest of these viruses, EBOV, were approved for human use: Ervebo VSV-based vaccine 2, as well as Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) heterologous prime/boost vaccine 3. ![]() Several filoviruses are responsible for fatal outbreaks of severe human diseases: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV) and Tai Forest virus (TAFV) 1. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |